FDA’s guidances, lightsensitive drugs [Design Issues]

posted by manan  – Ahmedabad, 2011-01-03 06:52 (5642 d 04:14 ago) – Posting: # 6386
Views: 10,326

Dear Phanni

The dosing procedure for chewable and film coated tablets is different as both fall into a different class of formulation.
As HS has said, it is always good to refer the FDA guidance on individual drugs before initiation of any study.

Dear HS
i do have a literature wherein it is mentioned that Montelukast shows instability when exposed to light leading to formation of cis-isomer as a major photoproduct and the degradation rate is least in sodium light then in UV or daylight. therefore it is better to carry out the trial in dark conditions to avoid exposure to direct light. the link which you have provided in last reply is also quiet helpful in this regard.

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,570 registered users;
115 visitors (1 registered, 114 guests [including 20 identified bots]).
Forum time: 12:06 CEST (Europe/Vienna)

The idea is to try and give all the information to help others
to judge the value of your contribution;
not just the information that leads to judgment
in one particular direction or another.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5